Mission & Vision
Based On The World’s first DNA Aptamer Patent, Becoming A Global Therapeutics and Healthcare Market Leader
Based On The World’s first DNA Aptamer Patent, Becoming A Global Therapeutics and Healthcare Market Leader
Entering the global healthcare market with the start of commercializing the first DNA Aptamer in worldwide
Intellectual Property Status
Area | Applied | PCT | Registered | Total |
---|---|---|---|---|
Aptamin® | 24 | 2 | 7 | 33 |
Therapeutics | 12 | 12 | ||
Early Diagnosis | 5 | 5 | ||
Other | ||||
Total | 41 | 2 | 7 | 50 |
Jung-Wook Shim
Aptamin Lab Co, CEO
ADT CAPS Co, V. President
Naturerepublic Co, V. President
The Face Shop, executive director
Economics at Seoul National University
Yoonsung Kim, M.D., Ph.D.
Rutgers University Medical School
Weill Cornell Medicine
Ph.D. in Medical School, Cornell Univ.
Jae-Seung Kang, Ph.D.
SNU therapeutics
Anatomy and Cell Biology
Ph.D. Seoul National University College of therapeutics
Yeongjeong Kim, Ph.D.
Dept. of Nursing Science,
Kyunghee University
Post-doc. Fellowship, Weill Medical School, Cornell Univ.
Ph.D, Kyunghee University